...
首页> 外文期刊>Nature clinical practice. Oncology >A remedy for biomarker addiction: back to rational anticancer drug development
【24h】

A remedy for biomarker addiction: back to rational anticancer drug development

机译:生物标志物成瘾的一种补救方法:回到合理的抗癌药物开发

获取原文
获取原文并翻译 | 示例
           

摘要

At first glance, the post-genomic era would seem to be an opportune time to rewrite the laws of cancer drug development, particularly for targeted agents that confer tumor growth-inhibition as their predominant therapeutic effect. The elucidation of various intracellular switches, cell surface receptors, and other potential 'druggable' targets in the human genome, the commonplace signaling aberrations in cancer, and the availability of remarkable imaging methodologies, should constitute a drug developer's dream toolbox for increasing the efficiency and reducing the risks associated with the development and approval of anticancer therapeutics. Alas, these efforts have enjoyed limited success at best. Unfortunately, the paradigms used in the development of trastuzumab (Herceptin~R, Genentech, San Francisco, CA) and imatinib mesylate (Gleevec , Novartis AG, Basel, Switzerland)-inhibitors of specific, robust molecular aberrations-cannot be extrapolated readily to most novel therapeutics. Other osten-
机译:乍一看,后基因组时代似乎是重写癌症药物开发法则的适当时机,特别是对于那些以抑制肿瘤生长为主要治疗效果的靶向药物而言。阐明人类基因组中的各种细胞内开关,细胞表面受体和其他潜在的“可拖累”靶标,癌症中常见的信号异常以及出色的成像方法的可用性,应成为药物开发人员梦dream以求的工具,以提高效率和降低与开发和批准抗癌疗法相关的风险。 efforts,这些努力充其量只能获得有限的成功。不幸的是,曲妥珠单抗(Herceptin〜R,Genentech,旧金山,加利福尼亚州)和伊马替尼甲磺酸盐(Gleevec,Novartis AG,​​巴塞尔,瑞士)的开发中使用的范例-特异性强健的分子畸变抑制剂无法轻易推导到大多数人新疗法。其他外观

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号